Renalytix (RENX) Share Price, News & Analysis

Company Overview

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.

Key Stats

• Today's Range: 7.20 to 8
• 50-Day Range: 7.38 to 9.75
• 52-Week Range: 7 to 74.90
• Volume: 194,880 shs
• Average Volume: 433,320 shs
• Market Capitalization: £12.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RENX Stock Analysis - Frequently Asked Questions

How have RENX shares performed this year?

Renalytix's stock was trading at GBX 15.50 at the start of the year. Since then, RENX stock has decreased by 51.6% and is now trading at GBX 7.50.
View the best growth stocks for 2024 here.

How do I buy shares of Renalytix?

Shares of RENX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Renalytix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Renalytix investors own include AutoZone (AZO), Beyond Meat (BYND), Helium One Global (HE1), HSBC (HSBA), Intel (INTC), ITM Power (ITM) and JD Sports Fashion (JD).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: LON:RENX
• CUSIP: N/A
• CIK: N/A
• Web: www.renalytixai.com
• Phone: 44 20 3139 2910
• Fax: N/A
• Employees: 102
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-33,460,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,073.18%
• Return on Assets: -93.54%

Debt

• Debt-to-Equity Ratio: 173.95
• Current Ratio: 0.53
• Quick Ratio: 2.42

Sales & Book Value

• Annual Sales: £2.29 million
• Price / Sales: 5.43
• Cash Flow: GBX 4.09 per share
• Price / Cash Flow: 1.84
• Book Value: GBX (5) per share
• Price / Book: -1.50

Miscellaneous

• Outstanding Shares: 165,930,000
• Free Float: N/A
• Market Cap: £12.44 million
• Optionable: Not Optionable
• Beta: 2.10